A series of stigmasterol and ergosterol derivatives, characterized by the presence of oxygenated functions at C-22 and/or C-23 positions, were designed as potential liver X receptor (LXR) agonists. The absolute configuration of the newly created chiral centers was definitively assigned for all the corresponding compounds. Among the 16 synthesized compounds, 21, 27, and 28 were found to be selective LXRα agonists, whereas 20, 22, and 25 showed good selectivity for the LXRβ isoform. In particular, 25 showed the same degree of potency as 22R-HC (3) at LXRβ, while it was virtually inactive at LXRα (EC50 = 14.51 μM). Interestingly, 13, 19, 20, and 25 showed to be LXR target gene-selective modulators, by strongly inducing the expression of ABCA1, while poorly or not activating the lipogenic genes SREBP1 and SCD1 or FASN, respectively.

Marinozzi, M., Castro Navas, F.F., Maggioni, D., Carosati, E., Bocci, G., Carloncelli, M., et al. (2017). Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists. JOURNAL OF MEDICINAL CHEMISTRY, 60(15), 6548-6562 [10.1021/acs.jmedchem.7b00091].

Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists

GIORGI, GIANLUCA;
2017-01-01

Abstract

A series of stigmasterol and ergosterol derivatives, characterized by the presence of oxygenated functions at C-22 and/or C-23 positions, were designed as potential liver X receptor (LXR) agonists. The absolute configuration of the newly created chiral centers was definitively assigned for all the corresponding compounds. Among the 16 synthesized compounds, 21, 27, and 28 were found to be selective LXRα agonists, whereas 20, 22, and 25 showed good selectivity for the LXRβ isoform. In particular, 25 showed the same degree of potency as 22R-HC (3) at LXRβ, while it was virtually inactive at LXRα (EC50 = 14.51 μM). Interestingly, 13, 19, 20, and 25 showed to be LXR target gene-selective modulators, by strongly inducing the expression of ABCA1, while poorly or not activating the lipogenic genes SREBP1 and SCD1 or FASN, respectively.
2017
Marinozzi, M., Castro Navas, F.F., Maggioni, D., Carosati, E., Bocci, G., Carloncelli, M., et al. (2017). Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists. JOURNAL OF MEDICINAL CHEMISTRY, 60(15), 6548-6562 [10.1021/acs.jmedchem.7b00091].
File in questo prodotto:
File Dimensione Formato  
GIORGI3_acs.jmedchem.7b00091-1 (3).pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 3.73 MB
Formato Adobe PDF
3.73 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
GIORGI G-Side-Chain Modified-Revised FINAL-PostPrint.pdf

accesso aperto

Descrizione: Accepted Manuscript
Tipologia: Post-print
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 1.71 MB
Formato Adobe PDF
1.71 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1030439